Clinical targeting of the TNF and TNFR superfamilies

被引：368

作者：

Croft, Michael ^{[1
]}

Benedict, Chris A. ^{[1
]}

Ware, Carl E. ^{[2
]}

机构：

[1] La Jolla Inst Allergy & Immunol, Div Immune Regulat, La Jolla, CA 92037 USA

[2] Sanford Burnham Med Res Inst, Infect & Inflammatory Dis Ctr, Lab Mol Immunol, La Jolla, CA 92037 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2013年 / 12卷 / 02期

基金：

美国国家卫生研究院;

关键词：

ANTI-CD40; MONOCLONAL-ANTIBODY; RELAPSED/REFRACTORY MULTIPLE-MYELOMA; SYSTEMIC-LUPUS-ERYTHEMATOSUS; COLLAGEN-INDUCED ARTHRITIS; CELL MATURATION ANTIGEN; B-LYMPHOCYTE STIMULATOR; VERSUS-HOST-DISEASE; CYTOKINE 1A TL1A; DEATH RECEPTOR 5; T-CELL;

D O I：

10.1038/nrd3930

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Inhibitors of tumour necrosis factor (TNF) are among the most successful protein-based drugs (biologics) and have proven to be clinically efficacious at reducing inflammation associated with several autoimmune diseases. As a result, attention is focusing on the therapeutic potential of additional members of the TNF superfamily of structurally related cytokines. Many of these TNF-related cytokines or their cognate receptors are now in preclinical or clinical development as possible targets for modulating inflammatory diseases and cancer as well as other indications. This Review focuses on the biologics that are currently in clinical trials for immune-related diseases and other syndromes, discusses the successes and failures to date as well as the expanding therapeutic potential of modulating the activity of this superfamily of molecules.

引用

页码：147 / 168

页数：22

共 220 条

[1] Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival [J].

Adams, AB ;

Shirasugi, N ;

Jones, TR ;

Durham, MM ;

Strobert, EA ;

Cowan, S ;

Rees, P ;

Hendrix, R ;

Price, K ;

Kenyon, NS ;

Hagerty, D ;

Townsend, R ;

Hollenbaugh, D ;

Pearson, TC ;

Larsen, CP .

JOURNAL OF IMMUNOLOGY, 2005, 174 (01) :542-550

[2] Expression of silencer of death domains and death-receptor-3 in normal human kidney and in rejecting renal transplants [J].

Al-Lamki, RS ;

Wang, J ;

Thiru, S ;

Pritchard, NR ;

Bradley, JA ;

Pober, JS ;

Bradley, JR .

AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (02) :401-411

[3] B-cell-derived lymphotoxin promotes castration-resistant prostate cancer [J].

Ammirante, Massimo ;

Luo, Jun-Li ;

Grivennikov, Sergei ;

Nedospasov, Sergei ;

Karin, Michael .

NATURE, 2010, 464 (7286) :302-U187

[4]

[Anonymous], [No title captured]

[5] Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma [J].

Ansell, Stephen M. ;

Witzig, Thomas E. ;

Inwards, David J. ;

Porrata, Luis F. ;

Ythier, Arnaud ;

Ferrande, Lee ;

Nestorov, Ivan ;

Devries, Todd ;

Dillon, Stacey R. ;

Hausman, Diana ;

Novak, Anne J. .

CLINICAL CANCER RESEARCH, 2008, 14 (04) :1105-1110

[6] A Human Anti-CD40 Monoclonal Antibody, 4D11, for Kidney Transplantation in Cynomolgus Monkeys: Induction and Maintenance Therapy [J].

Aoyagi, T. ;

Yamashita, K. ;

Suzuki, T. ;

Uno, M. ;

Goto, R. ;

Taniguchi, M. ;

Shimamura, T. ;

Takahashi, N. ;

Miura, T. ;

Okimura, K. ;

Itoh, T. ;

Shimizu, A. ;

Furukawa, H. ;

Todo, S. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (08) :1732-1741

[7] TNF neutralization in MS - Results of a randomized, placebo-controlled multicenter study [J].

Arnason, BGW ;

Jacobs, G ;

Hanlon, M ;

Clay, BH ;

Noronha, ABC ;

Auty, A ;

Davis, B ;

Nath, A ;

Bouchard, JP ;

Belanger, C ;

Gosselin, F ;

Thibault, M ;

Duquette, P ;

Bourgoin, P ;

DuBois, R ;

Girard, M ;

Ebers, GC ;

Rice, GPA ;

Vandervoort, MK ;

Francis, GS ;

Duncan, L ;

Lapierre, Y ;

Freedman, MS ;

Christie, SN ;

Rabinovitch, HE ;

Patry, D ;

Murphy, WF ;

Peters, S ;

McGuiness, SD ;

Murray, TJ ;

Bhan, V ;

Maxner, CE ;

Van Dorpe, R ;

Oger, JJ ;

Nelson, J ;

Morrison, W ;

Bogle, N ;

Beall, S ;

Vorobeychick, G ;

Hiltbrunner, AV ;

Bock, J ;

Habil ;

Lesslauer, W ;

Li, DKB ;

Paty, DW ;

Zhao, GJ .

NEUROLOGY, 1999, 53 (03) :457-465

[8] Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL) [J].

Ashkenazi, Avi ;

Holland, Pamela ;

Eckhardt, S. Gail .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) :3621-3630

[9] Glucocorticoid-induced tumour necrosis factor receptor-related protein-mediated macrophage stimulation may induce cellular adhesion and cytokine expression in rheumatoid arthritis [J].

Bae, E. ;

Kim, W.-J. ;

Kang, Y.-M. ;

Suk, K. ;

Koh, E.-M. ;

Cha, H.-S. ;

Ahn, K.-S. ;

Huh, T.-L. ;

Lee, W.-H. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 148 (03) :410-418

[10] Reverse signaling initiated from GITRL induces NF-κB activation through ERK in the inflammatory activation of macrophages [J].

Bae, Eun Mi ;

Kim, Won-Jung ;

Suk, Kyoungho ;

Kang, Young-Mo ;

Park, Jeong-Euy ;

Kim, Won Young ;

Choi, Eun Mi ;

Choi, Beom Kyu ;

Kwon, Byoung S. ;

Lee, Won-Ha .

MOLECULAR IMMUNOLOGY, 2008, 45 (02) :523-533

← 1 2 3 4 5 6 7 8 9 10 →